PTC Therapeutics, Inc. (PTCT) Earnings Call Analysis

NASDAQ · Healthcare · Biotechnology

22/25

Growth 5 Margin 5 Expansion 5 Platform 4 Financial 3

latest quarter score

Earnings Reports

22
PTC Therapeutics (PTCT) Q2 2026: Suffiance Drives 21% Sequential Growth, Global Launch Expands Revenue Base
July 31, 2026
24
PTC Therapeutics (PTCT) Q1 2026: Suffiance Drives 47% Product Revenue Growth, Recasts Global Rare Disease Trajectory
May 08, 2026
19
PTC Therapeutics (PTCT) Q4 2025: Suffiance Launch Drives 36% Product Revenue Growth Target
February 23, 2026
19
PTC Therapeutics (PTCT) Q3 2025: Suffiance Launch Adds $19.6M, Broad Uptake Signals Durable PKU Franchise
November 05, 2025
17
PTC Therapeutics (PTCT) Q2 2025: Suffiance Launch Targets $1B+ US Opportunity as DMD Franchise Holds 25% EU Revenue
August 08, 2025
23
PTC Therapeutics (PTCT) Q1 2025: $2B Cash Bolsters Multi-Asset Launch Cycle
July 07, 2025
PTC Therapeutics (PTCT) Q4 2024: $1 Billion Novartis Deal and Multiple Launches Set Growth Stage
February 27, 2025

Browse all companies